Citi raised the firm’s price target on GE HealthCare (GEHC) to $93 from $89 and keeps a Buy rating on the shares. The company reported a Q2 beat and guidance raise but the stock sold on order book concerns and its commentary about China, the analyst tells investors in a research note. Citi sees a robust product pipeline for GE HealthCare.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on GEHC:
- Cautious Outlook for GE Healthcare Technologies: Hold Rating Maintained Amid Market Expectations and Trade Uncertainties
- GE HealthCare Reports Strong Q2 2025 Performance
- GE Healthcare’s Earnings Call Highlights Growth Amid Challenges
- Morning Movers: Wingstop jumps after second quarter report and dividend raise
- GE HealthCare reports Q2 adjusted EPS $1.06, consensus 92c